Phathom Pharmaceuticals Inc (PHAT) Stock Analysis
Verdict: WATCH (do not buy)
VOQUEZNA's 110% revenue ramp is eclipsed by a sub-10-month cash runway and $211.8M debt load, making equity dilution the primary swing risk.
Investment score: 43/100
Analysis as of
Is Phathom Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
Phathom Pharmaceuticals displays strong top-line momentum with $175.11M in 2025 revenue (+110% YoY) and 82.92% gross margins, but severe cash burn (-$166.78M operating cash flow) and $211.80M in debt threaten equity holders with near-term dilution.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 25/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 60/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Phathom Pharmaceuticals Inc opportunities and risks
What speaks for PHAT
- Rapid VOQUEZNA commercial adoption driving 110% revenue growth
What speaks against PHAT
- Imminent cash exhaustion and secondary equity dilution
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PHAT | n/a | 2.4x | n/a | 82.9% | -41.3% | -6.4% |
| LXRX | n/a | 17.7x | n/a | 98.9% | -147.4% | -10.9% |
| COLL | 14.4x | 0.9x | 3.0x | 60.0% | 5.9% | 45.9% |
| AQST | n/a | 11.2x | n/a | 67.0% | -144.6% | -7.6% |
| CRMD | 3.1x | 1.3x | 1.9x | 82.8% | 40.5% | 43.0% |
| Peer median | n/a | 6.2x | n/a | 74.9% | -69.4% | 17.7% |
Frequently asked questions about Phathom Pharmaceuticals Inc (PHAT)
Is PHAT stock a good investment?
The TradeMates model rates Phathom Pharmaceuticals Inc as WATCH (do not buy) with an investment score of 43/100. Phathom Pharmaceuticals displays strong top-line momentum with $175.11M in 2025 revenue (+110% YoY) and 82.92% gross margins, but severe cash burn (-$166.78M operating cash flow) and $211.80M in debt threaten equity holders with near-term dilution. This is algorithmic model output, not personal investment advice.
Is PHAT stock a buy?
The TradeMates model verdict for PHAT is WATCH (do not buy) with an investment score of 43/100. Treat this as a model signal to review, not a personal buy recommendation.